Biggest changeThe CODM does not review assets by segment in his resource allocation and therefore, assets by segment are not disclosed below. 31 Table of Contents The following tables set forth the Company’s consolidated statements of operations by business segment (in thousands ): Year Ended December 31, 2024 Inpatient Services Homecare and Hospice All Other Total Revenues: Net patient revenues $ 1,111,300 $ 140,459 $ – $ 1,251,759 Other revenues 1,315 – 44,863 46,178 Government grant income – – 9,445 9,445 Net operating revenues and grant income 1,112,615 140,459 54,308 1,307,382 Costs and Expenses: Salaries, wages and benefits 668,029 85,712 57,189 810,930 Other operating 280,867 25,927 14,596 321,390 Facility rent 33,787 2,295 7,100 43,182 Depreciation and amortization 37,988 737 3,260 41,985 Interest 4,135 – – 4,135 Total costs and expenses 1,024,806 114,671 82,145 1,221,622 Income (loss) before non-operating income 87,809 25,788 (27,837 ) 85,760 Non-operating income – – 19,690 19,690 Unrealized gains on marketable equity securities – – 30,958 30,958 Income before income taxes $ 87,809 $ 25,788 $ 22,811 $ 136,408 Year Ended December 31, 2023 Inpatient Services Homecare and Hospice All Other Total Revenues: Net patient revenues $ 956,077 $ 131,537 $ – $ 1,087,614 Other revenues 1,141 – 52,789 53,930 Net operating revenues 957,218 131,537 52,789 1,141,544 Costs and Expenses: Salaries, wages and benefits 589,279 80,610 42,455 712,344 Other operating 254,559 23,529 10,095 288,183 Facility rent 32,542 2,172 6,811 41,525 Depreciation and amortization 38,172 786 3,076 42,034 Interest 324 – – 324 Total costs and expenses 914,876 107,097 62,437 1,084,410 Income (loss) before non-operating income 42,342 24,440 (9,648 ) 57,134 Non-operating income – – 16,660 16,660 Unrealized gains on marketable equity securities – – 14,944 14,944 Income before income taxes $ 42,342 $ 24,440 $ 21,956 $ 88,738 32 Table of Contents Year Ended December 31, 2022 Inpatient Services Homecare and Hospice All Other Total Revenues: Net patient revenues $ 900,231 $ 128,854 $ – $ 1,029,085 Other revenues 136 – 45,060 45,196 Government grant income 11,457 – – 11,457 Net operating revenues and grant income 911,824 128,854 45,060 1,085,738 Costs and Expenses: Salaries, wages and benefits 580,707 77,688 27,774 686,169 Other operating 251,355 26,319 11,698 289,372 Facility rent 32,526 2,327 6,124 40,977 Depreciation and amortization 36,522 691 3,276 40,489 Interest 563 – – 563 Recovery of assets – – (3,728 ) (3,728 ) Total costs and expenses 901,673 107,025 45,144 1,053,842 Income before non-operating income 10,151 21,829 (84 ) 31,896 Non-operating income – – 11,141 11,141 Unrealized losses on marketable equity securities – – (15,806 ) (15,806 ) Income (loss) before income taxes $ 10,151 $ 21,829 $ (4,749 ) $ 27,231 Non-GAAP Financial Presentation The Company is providing certain non-GAAP financial measures as the Company believes that these figures are helpful in allowing investors to more accurately assess the ongoing nature of the Company’s operations and measure the Company’s performance more consistently across periods.
Biggest changeThe CODM does not review assets by segment in his resource allocation and therefore, assets by segment are not disclosed below. 31 The following tables set forth the Company’s consolidated statements of operations by business segment (in thousands ): Year Ended December 31, 2025 Inpatient Services Homecare and Hospice All Other Total Revenues: Net patient revenues $ 1,315,545 $ 154,086 $ – $ 1,469,631 Other revenues 1,467 – 46,683 48,150 Net operating revenues 1,317,012 154,086 46,683 1,517,781 Costs and Expenses: Salaries, wages and benefits 775,477 93,535 52,068 921,080 Other operating 336,746 27,537 12,919 377,202 Facility rent 35,972 2,373 7,882 46,227 Depreciation and amortization 41,066 581 3,273 44,920 Total costs and expenses 1,189,261 124,026 76,142 1,389,429 Income (loss) from operations 127,751 30,060 (29,459 ) 128,352 Non-operating income – – 18,107 18,107 Interest expense (6,371 ) – – (6,371 ) Unrealized gains on marketable equity securities – – 22,344 22,344 Income before income taxes $ 121,380 $ 30,060 $ 10,992 $ 162,432 Year Ended December 31, 2024 Inpatient Services Homecare and Hospice All Other Total Revenues: Net patient revenues $ 1,111,300 $ 140,459 $ – $ 1,251,759 Other revenues 1,315 – 44,863 46,178 Government stimulus income – – 9,445 9,445 Net operating revenues and stimulus income 1,112,615 140,459 54,308 1,307,382 Costs and Expenses: Salaries, wages and benefits 668,029 85,712 57,189 810,930 Other operating 280,867 25,927 14,596 321,390 Facility rent 33,787 2,295 7,100 43,182 Depreciation and amortization 37,988 737 3,260 41,985 Total costs and expenses 1,020,671 114,671 82,145 1,217,487 Income (loss) from operations 91,944 25,788 (27,837 ) 89,895 Non-operating income – – 19,690 19,690 Interest expense (4,135 ) – – (4,135 ) Unrealized gains on marketable equity securities – – 30,958 30,958 Income before income taxes $ 87,809 $ 25,788 $ 22,811 $ 136,408 32 Year Ended December 31, 2023 Inpatient Services Homecare and Hospice All Other Total Revenues: Net patient revenues $ 956,077 $ 131,537 $ – $ 1,087,614 Other revenues 1,141 – 52,789 53,930 Net operating revenues 957,218 131,537 52,789 1,141,544 Costs and Expenses: Salaries, wages and benefits 589,279 80,610 42,455 712,344 Other operating 254,559 23,529 10,095 288,183 Facility rent 32,542 2,172 6,811 41,525 Depreciation and amortization 38,172 786 3,076 42,034 Total costs and expenses 914,552 107,097 62,437 1,084,086 Income (loss) from operations 42,666 24,440 (9,648 ) 57,458 Non-operating income – – 16,660 16,660 Interest expense (324 ) – – (324 ) Unrealized gains on marketable equity securities – – 14,944 14,944 Income before income taxes $ 42,342 $ 24,440 $ 21,956 $ 88,738 Results of Operations The following table and discussion set forth items from the consolidated statements of operations as a percentage of net operating revenues and grant income for the years ended December 31, 2025, 2024 and 2023.
The exiting of these operations resulted in other operating expenses decreasing $7,101,000 for the year ended December 31, 2024 compared to the prior year. We continue to face inflationary pressures in certain categories within other operating expenses as well, such as food/dietary supplies and drugs/pharmaceutical supplies. Facility rent expense increased $1,657,000, or 4.0%, to $43,182,000.
The exiting of these operations resulted in other operating expenses decreasing $7,101,000 for the year ended December 31, 2024 compared to the prior year. We continue to face inflationary pressures in certain categories within other operating expenses as well, such as food/dietary supplies and drugs/pharmaceutical supplies. Facility rent expense increased $1,657,000, or 4.0%, to $43,182,000 in 2024.
Depreciation and amortization decreased 0.1% to $41,985,000. Interest expense increased $3,811,000 to $4,135,000 in 2024 from $324,000 in 2023. At December 31, 2024, we have outstanding long-term debt of $137,000,000 due to the White Oak acquisition. In 2023, we didn't have any outstanding long-term debt.
Depreciation and amortization decreased 0.1% to $41,985,000 in 2024. Interest expense increased $3,811,000 to $4,135,000 in 2024 from $324,000 in 2023. At December 31, 2024, we have outstanding long-term debt of $137,000,000 due to the White Oak acquisition. In 2023, we didn't have any outstanding long-term debt.
Other income Non–operating income increased by $3,030,000, or 18.2% to $19,690,000 compared to the prior year, as further detailed in Note 5 to our consolidated financial statements. We recorded unrealized gains in the amount of $30,958,000 for the increase in fair value of our marketable equity securities portfolio for the year ended December 31, 2024.
Other income Non–operating income increased by $3,030,000, or 18.2% to $19,690,000 in 2024 compared to the prior year, as further detailed in Note 5 to our consolidated financial statements. We recorded unrealized gains in the amount of $30,958,000 for the increase in fair value of our marketable equity securities portfolio for the year ended December 31, 2024.
Excluding the unrealized gains and losses in our marketable equity securities portfolio and other non-GAAP adjustments, adjusted net income was $76,862,000 for the year ended December 31, 2024 compared to $54,934,000 for the same period a year ago.
Excluding the unrealized gains in our marketable equity securities portfolio and other non-GAAP adjustments, adjusted net income was $76,862,000 for the year ended December 31, 2024 compared to $54,934,000 for the same period a year ago.
Guarantees At December 31, 2024, we have no agreements to guarantee the debt obligations of other parties. We have no outstanding letters of credit. We may or may not in the future elect to use financial derivative instruments to hedge interest rate exposure in the future. At December 31, 2024, we did not participate in any such financial instruments.
Guarantees At December 31, 2025, we have no agreements to guarantee the debt obligations of other parties. We have no outstanding letters of credit. We may or may not in the future elect to use financial derivative instruments to hedge interest rate exposure in the future. At December 31, 2025, we did not participate in any such financial instruments.
Also included in net patient revenues for the years ended December 31, 2024 and 2023, respectively, is $12,749,000 and $20,214,000 of supplemental Medicaid payments that were received to help mitigate the healthcare workforce crisis and the inflationary labor market. 35 Table of Contents Other revenues in 2024 were $46,178,000, a decrease of $7,752,000, or 14.4%, as further detailed in Note 4 to our consolidated financial statements.
Also included in net patient revenues for the years ended December 31, 2024 and 2023, respectively, is $12,749,000 and $20,214,000 of supplemental Medicaid payments that were received to help mitigate the healthcare workforce crisis and the inflationary labor market. 36 Other revenues in 2024 were $46,178,000, a decrease of $7,752,000, or 14.4%, as further detailed in Note 3 to our consolidated financial statements.
At December 31, 2024, we operate or manage 80 skilled nursing facilities with 10,341 1icensed beds, 26 assisted living facilities with 1,413 units, nine independent living facilities, three behavioral health hospitals, 34 homecare agencies, and 33 hospice agencies located in 9 states.
At December 31, 2025, we operate or manage 80 skilled nursing facilities with 10,329 1icensed beds, 26 assisted living facilities with 1,413 units, nine independent living facilities, three behavioral health hospitals, 34 homecare agencies, and 33 hospice agencies located in 9 states.
Our future performance will be affected by business, economic, financial and other factors, including potential changes in state and federal government payment rates for health care, customer demand, success of our marketing efforts, pressures from competitors, and the state of the economy, including the state of financial and credit markets, as well as many unforeseen factors. 40 Table of Contents Contingencies See Note 17 to the consolidated financial statements for additional information on pending litigation and other contingencies.
Our future performance will be affected by business, economic, financial and other factors, including potential changes in state and federal government payment rates for health care, customer demand, success of our marketing efforts, pressures from competitors, and the state of the economy, including the state of financial and credit markets, as well as many unforeseen factors. 41 Contingencies See Note 16 to the consolidated financial statements for additional information on pending litigation and other contingencies.
We also own the real estate of 10 healthcare properties and lease these properties to third party operators. 29 Table of Contents Executive Summary Earnings To monitor our earnings, we have developed budgets and management reports to monitor labor, census, and the composition of revenues.
We also own the real estate of 10 healthcare properties and lease these properties to third party operators. 30 Executive Summary Earnings To monitor our earnings, we have developed budgets and management reports to monitor labor, census, and the composition of revenues.
Accrued Risk Reserves Our accrued professional liability and workers’ compensation reserves totaled $103,616,000 and $103,259,000 at December 31, 2024 and 2023, respectively, and are a primary area of management focus. We have set aside restricted cash and restricted marketable securities to fund our professional liability and workers’ compensation reserves.
Accrued Risk Reserves Our accrued professional liability and workers’ compensation reserves totaled $121,595,000 and $103,616,000 at December 31, 2025 and 2024, respectively, and are a primary area of management focus. We have set aside restricted cash and restricted marketable securities to fund our professional liability and workers’ compensation reserves.
We recorded unrealized gains in the amount of $14,944,000 for the increase in fair value of our marketable equity securities portfolio for the year ended December 31, 2023. The marketable equity securities portfolio consists mainly of publicly-traded healthcare REIT’s and other blue-chip public companies held within our insurance companies.
We recorded unrealized gains in the amount of $22,344,000 for the increase in fair value of our marketable equity securities portfolio for the year ended December 31, 2025. The marketable equity securities portfolio consists mainly of publicly-traded healthcare REIT’s and other blue-chip public companies held within our insurance companies.
The tables below summarize NHC's overall performance in these Five-Star ratings versus the skilled nursing industry as of December 31, 2024: NHC Ratings Industry Ratings Total number of skilled nursing facilities, end of period 80 Number of 4 and 5-star rated skilled nursing facilities 46 Percentage of 4 and 5-star rated skilled nursing facilities 57% 35% Average rating for all skilled nursing facilities, end of period 3.6 2.8 Development and Growth We are undertaking to expand our post–acute and senior health care operations while protecting our existing operations and markets.
The tables below summarize NHC's overall performance in these Five-Star ratings versus the skilled nursing industry as of December 31, 2025: NHC Ratings Industry Ratings Total number of skilled nursing facilities, end of period 80 Number of 4 and 5-star rated skilled nursing facilities 50 Percentage of 4 and 5-star rated skilled nursing facilities 62.5% 38.6% Average rating for all skilled nursing facilities, end of period 3.83 2.95 Development and Growth We are undertaking to expand our post–acute and senior health care operations while protecting our existing operations and markets.
Long – term liquidity We expect to meet our long–term liquidity requirements primarily from our cash flows from operating activities, our current cash on hand of $76,121,000, our unrestricted marketable equity securities of $140,064,000, and our borrowing capacity on the $50 million available line of credit.
Long – term liquidity We expect to meet our long–term liquidity requirements primarily from our cash flows from operating activities, our current cash on hand of $92,829,000, our unrestricted marketable equity securities of $162,972,000, and our borrowing capacity on the $50 million available line of credit.
The White Oak portfolio consists of 15 skilled nursing facilities, two assisted living facilities, and four independent living facilities. The White Oak operations have 1,928 licensed skilled nursing beds, 48 assisted living units, and 302 independent living units in the states of South Carolina and North Carolina.
(“White Oak”). The White Oak portfolio consisted of 15 skilled nursing facilities, two assisted living facilities, four independent living facilities and a long-term care pharmacy. The White Oak operations have 1,928 licensed skilled nursing beds, 48 assisted living units, and 302 independent living units in the states of South Carolina and North Carolina.
Total costs and expenses Total costs and expenses were $1,221,622,000 for 2024, an increase of $137,212,000, or 12.7%, from $1,084,410,000 in 2023. Salaries, wages, and benefits increased $98,586,000, or 13.8%, to $810,930,000 from $712,344,000.
Total costs and expenses Total costs and expenses were $1,217,487,000 for 2024, an increase of $133,401,000, or 12.3%, from $1,084,086,000 in 2023. Salaries, wages, and benefits increased $98,586,000, or 13.8%, to $810,930,000 in 2024 from $712,344,000 in 2023.
Our primary uses of cash include salaries, wages and other operating costs of our healthcare operations, the cost of additions to and acquisitions of real property, facility rent expenses, and dividend distributions. These sources and uses of cash are reflected in our consolidated statements of cash flows and are discussed in further detail below.
Our primary uses of cash include salaries, wages and other operating costs of our healthcare operations, the cost of additions to and acquisitions of real property, facility rent expenses, and dividend distributions.
Louis, MO June 2022 Hospice New Agency 1 agency Cedar Bluff, VA March 2023 Skilled Nursing Acquisition 66 beds Nashville, TN May 2023 Homecare New Agency 1 agency Tallahassee, FL May 2023 Assisted Living Facility New Operations 135 units Vero Beach, FL July 2023 Assisted Living Facility New Operations 95 units Merritt Island, FL July 2023 Assisted Living Facility New Operations 100 units Stuart, FL July 2023 Hospice New Agency 1 agency Morristown, TN April 2024 Hospice New Agency 1 agency Lawrenceburg, TN July 2024 Hospice New Agency 1 agency Wytheville, VA August 2024 Hospice New Agency 1 agency Clinton, TN October 2024 30 Table of Contents On August 1, 2024, the Company purchased the White Oak portfolio, including its long-term care pharmacy.
Type of Operation Description Size Location Placed in Service Hospice New Agency 1 agency Cedar Bluff, VA March 2023 Skilled Nursing Acquisition 66 beds Nashville, TN May 2023 Homecare New Agency 1 agency Tallahassee, FL May 2023 Assisted Living Facility New Operations 135 units Vero Beach, FL July 2023 Assisted Living Facility New Operations 95 units Merritt Island, FL July 2023 Assisted Living Facility New Operations 100 units Stuart, FL July 2023 Hospice New Agency 1 agency Morristown, TN April 2024 Hospice New Agency 1 agency Lawrenceburg, TN July 2024 Hospice New Agency 1 agency Wytheville, VA August 2024 Hospice New Agency 1 agency Clinton, TN October 2024 On August 1, 2024, the Company purchased the assets of White Oak Management, Inc.
The increase in non-GAAP earnings for the year ended December 31, 2023 compared to the same period in the prior year was primarily due to the continued occupancy increase in our skilled nursing facilities, skilled nursing per diem increases from some of our government payors, and the continued reduction of nurse agency staffing expense within our operations.
The increase in non-GAAP earnings for the year ended December 31, 2025 compared to 2024 was primarily due to the continued increase in skilled nursing census, skilled nursing per diem increases from some of our governmental payors, the continued reduction of agency staffing expense, and the White Oak operations being accretive to earnings.
In addition to cash flows from operations, we have current cash on hand of $76,121,000 and unrestricted marketable equity securities of $140,064,000. We also have unencumbered real estate and the borrowing capacity on our $50 million available line of credit.
Short – term liquidity We expect to meet our short–term liquidity requirements primarily from our cash flows from operating activities. In addition to cash flows from operations, we have current cash on hand of $92,829,000 and unrestricted marketable equity securities of $162,972,000. We also have unencumbered real estate and the borrowing capacity on our $50 million available line of credit.
Cash provided by operating activities consisted of net income of $102,086,000 and adjustments for non–cash items of $32,027,000. There was cash used for working capital needs in the amount of $25,717,000 for the year ended December 31, 2024, which was primarily driven by the White Oak acquisition.
Cash provided by operating activities consisted of net income of $122,606,000 and adjustments for non–cash items of $30,244,000. There was cash provided by working capital needs in the amount of $33,395,000 for the year ended December 31, 2025. In 2024, there was cash used for working capital in the amount of $25,717,000.
Excluding the unrealized gains and losses in our marketable equity securities portfolio and other non-GAAP adjustments, adjusted net income was $54,934,000 for the year ended December 31, 2023 compared to $37,323,000 in the prior year.
Excluding the unrealized gains in our marketable equity securities portfolio and other non-GAAP adjustments, adjusted net income was $104,067,000 for the year ended December 31, 2025 compared to $76,862,000 for the same period a year ago.
In 2023, there was cash provided by working capital in the amount of $17,396,000. Included in the adjustments for non-cash items are depreciation expense, equity in earnings of unconsolidated investments, unrealized losses on our marketable equity securities, gain on the sale of an unconsolidated company, deferred taxes, and stock compensation.
Included in the adjustments for non-cash items are depreciation expense, equity in earnings of unconsolidated investments, unrealized gains on our marketable equity securities, gain on the sale of property and equipment, deferred taxes, and stock compensation.
Period to Period Increase (Decrease) 2024 vs. 2023 2023 vs. 2022 Amount Percent Amount Percent Revenues: Net patient revenues $ 164,145 15.1 % $ 58,529 5.7 % Other revenues (7,752 ) (14.4 ) 8,734 19.3 Government grant income 9,445 100.0 (11,457 ) (100.0 ) Net operating revenues and grant income 165,838 14.5 55,806 5.1 Costs and Expenses: Salaries, wages and benefits 98,586 13.8 26,175 3.8 Other operating 33,207 11.5 (1,189 ) (0.4 ) Facility rent 1,657 4.0 548 1.3 Depreciation and amortization (49 ) (0.1 ) 1,545 3.8 Interest 3,811 1,176.2 (239 ) (42.5 ) Impairment (recovery) of assets – – 3,728 100.0 Total costs and expenses 137,212 12.7 30,568 2.9 Income from operations 28,626 50.1 25,238 79.1 Non–operating income 3,030 18.2 5,519 49.5 Unrealized gains (losses) on marketable equity securities 16,014 107.2 30,750 194.5 Income before income taxes 47,670 53.7 61,507 225.9 Income tax provision (10,872 ) (46.4 ) (16,196 ) (223.3 ) Net income 36,798 56.4 45,311 226.8 Net (income) loss attributable to noncontrolling interest (1,669 ) (110.5 ) (958 ) (38.8 ) Net income attributable to common stockholders of NHC $ 35,129 52.6 % $ 44,353 197.6 % 2024 Compared to 2023 Net operating revenues and grant income for the year ended December 31, 2024 totaled $1,307,382,000 compared to $1,141,544,000 for the year ended December 31, 2023, an increase of 14.5%.
Period to Period Increase (Decrease) 2025 vs. 2024 2024 vs. 2023 Amount Percent Amount Percent Revenues: Net patient revenues $ 217,872 17.4 % $ 164,145 15.1 % Other revenues 1,972 4.3 (7,752 ) (14.4 ) Government stimulus income (9,445 ) (100.0 ) 9,445 100.0 Net operating revenues and stimulus income 210,399 16.1 165,838 14.5 Costs and Expenses: Salaries, wages and benefits 110,150 13.6 98,586 13.8 Other operating 55,812 17.4 33,207 11.5 Facility rent 3,045 7.1 1,657 4.0 Depreciation and amortization 2,935 7.0 (49 ) (0.1 ) Total costs and expenses 171,942 14.1 133,401 12.3 Income from operations 38,457 42.8 32,437 56.5 Non–operating income (1,583 ) (8.0 ) 3,030 18.2 Interest expense (2,236 ) (54.1 ) 3,811 1,176.2 Unrealized gains on marketable equity securities (8,614 ) (27.8 ) 16,014 107.2 Income before income taxes 26,024 19.1 47,670 53.7 Income tax provision (5,504 ) (16.0 ) (10,872 ) (46.4 ) Net income 20,520 20.1 36,798 56.4 Net (income) loss attributable to noncontrolling interest (2,432 ) (1,529.6 ) (1,669 ) (110.5 ) Net income attributable to common stockholders of NHC $ 18,088 17.7 % $ 35,129 52.6 % 2025 Compared to 2024 Net operating revenues and stimulus income for the year ended December 31, 2025 totaled $1,517,781,000 compared to $1,307,382,000 for the year ended December 31, 2024, an increase of 16.1%.
The following is a summary of our sources and uses of cash flows (dollars in thousands) : Year Ended One Year Change Year Ended One Year Change 12/31/24 12/31/23 $ % 12/31/23 12/31/22 $ % Cash, cash equivalents, restricted cash, and restricted cash equivalents at beginning of period $ 125,968 $ 74,865 $ 51,103 68.3 % $ 74,865 $ 119,743 $ (44,878 ) (37.5 )% Cash provided by operating activities 107,303 111,216 (3,913 ) (3.5 ) 111,216 8,742 102,474 1,172.2 Cash used in investing activities (236,693 ) (17,568 ) (219,125 ) (1,247.3 ) (17,568 ) (5,978 ) (11,590 ) (193.9 ) Cash provided by / (used in) financing activities 100,344 (42,545 ) 142,889 335.9 (42,545 ) (47,642 ) 5,097 10.7 Cash, cash equivalents, restricted cash, and restricted cash equivalents at end of period $ 96,922 $ 125,968 $ (29,046 ) (23.1 )% $ 125,968 $ 74,865 $ 51,103 68.3 % 39 Table of Contents Operating Activities Net cash provided by operating activities for the year ended December 31, 2024 was $107,303,000 as compared to $111,216,000 and $8,742,000 for the years ended December 31, 2023 and 2022, respectively.
These sources and uses of cash are reflected in our consolidated statements of cash flows and are discussed in further detail below. 39 The following is a summary of our sources and uses of cash flows (dollars in thousands) : Year Ended One Year Change Year Ended One Year Change 12/31/25 12/31/24 $ % 12/31/24 12/31/23 $ % Cash, cash equivalents, restricted cash, and restricted cash equivalents at beginning of period $ 96,922 $ 125,968 $ (29,046 ) (23.1 )% $ 125,968 $ 74,865 $ 51,103 68.3 % Cash provided by operating activities 185,078 107,303 77,775 72.5 107,303 111,216 (3,913 ) (3.5 ) Cash used in investing activities (33,858 ) (236,693 ) 202,835 85.7 (236,693 ) (17,568 ) (219,125 ) (1,247.3 ) Cash (used in) / provided by financing activities (135,955 ) 100,344 (236,299 ) (235.5 ) 100,344 (42,545 ) 142,889 335.9 Cash, cash equivalents, restricted cash, and restricted cash equivalents at end of period $ 112,187 $ 96,922 $ 15,265 15.7 % $ 96,922 $ 125,968 $ (29,046 ) (23.1 )% 40 Operating Activities Net cash provided by operating activities for the year ended December 31, 2025 was $185,078,000 as compared to $107,303,000 and $111,216,000 for the years ended December 31, 2024 and 2023, respectively.
Income taxes The income tax provision for 2024 is $34,322,000 (an effective income tax rate of 25.2%). 36 Table of Contents 2023 Compared to 2022 Net operating revenues and grant income for the year ended December 31, 2023 totaled $1,141,544,000 compared to $1,085,738,000 for the year ended December 31, 2022, an increase of 5.1%.
Income taxes The income tax provision for 2025 is $39,826,000 (an effective income tax rate of 24.5%). 35 2024 Compared to 2023 Net operating revenues and stimulus income for the year ended December 31, 2024 totaled $1,307,382,000 compared to $1,141,544,000 for the year ended December 31, 2023, an increase of 14.5%.
In December 2023, we contributed land to a newly-formed limited liability company resulting in an equity interest in the new joint venture. The fair value of the land contributed to the entity was $8,000,000 and the related cost basis in the land was $1,770,000, which resulted in a gain of $6,230,000.
During the second quarter of 2025, we contributed land to a newly-formed limited liability company resulting in an equity interest in the new entity. The fair value of the land contributed to the new entity was $5,625,000. The related cost basis of the contributed land was $2,019,000, which resulted in a gain of $3,606,000.
Included in net patient revenues for the years ended December 31, 2023 and 2022, respectively, is $20,214,000 and $19,442,000 of supplemental Medicaid payments that were received to help mitigate the inflationary labor and medical supplies costs caused by the pandemic. 37 Table of Contents Other revenues in 2023 were $53,930,000, an increase of $8,734,000, or 19.3%, as further detailed in Note 4 to our consolidated financial statements.
Also included in net patient revenues for the years ended December 31, 2025 and 2024, respectively, is $7,246,000 and $12,749,000 of supplemental Medicaid payments that were received to help mitigate the healthcare workforce crisis and the inflationary labor market. 34 Other revenues in 2025 were $48,150,000, an increase of $1,972,000, or 4.3%, as further detailed in Note 3 to our consolidated financial statements.
For the year ended December 31, 2022, included are two behavioral health hospitals, one hospice agency, and one homecare agency. 33 Table of Contents The table below provides reconciliations of GAAP to non-GAAP items ( dollars in thousands, except per share data ): Year Ended December 31, 2024 2023 2022 Net income attributable to National HealthCare Corporation $ 101,927 $ 66,798 $ 22,445 Non-GAAP adjustments: Unrealized (gains) losses on marketable equity securities (30,958 ) (14,944 ) 15,806 Stock-based compensation expense 4,160 2,782 2,612 Operating results for newly-opened operations not at full capacity 130 2,359 5,416 Acquisition-related expenses 3,266 – – Employee retention credit (9,445 ) – – Gain on sale of unconsolidated company (1,024 ) – – Gain on sale of property and equipment – (6,230 ) – Impairment (recovery) of assets – – (3,728 ) Income tax expense (benefit) on non-GAAP adjustments 8,806 4,169 (5,228 ) Non-GAAP Net Income $ 76,862 $ 54,934 $ 37,323 GAAP diluted earnings per share $ 6.53 $ 4.34 $ 1.45 Non-GAAP adjustments: Unrealized (gains) losses on marketable equity securities (1.47 ) (0.72 ) 0.76 Stock-based compensation expense 0.20 0.13 0.13 Operating results for newly-opened operations not at full capacity 0.01 0.10 0.26 Acquisition-related expenses 0.16 – – Employee retention credit (0.45 ) – – Gain on sale of unconsolidated company (0.05 ) – – Gain on sale of property and equipment – (0.30 ) – Impairment (recovery) of assets – – (0.18 ) Non-GAAP diluted earnings per share $ 4.93 $ 3.55 $ 2.42 Results of Operations The following table and discussion set forth items from the consolidated statements of operations as a percentage of net operating revenues and grant income for the years ended December 31, 2024, 2023 and 2022.
Specifically, the Company believes the presentation of non-GAAP financial information that excludes the unrealized gains or losses on our marketable equity securities, stock-based compensation expense, gains on sale of property and equipment, operating results for start-up healthcare operations not at full capacity, acquisition related expenses, the recognition of the employee retention credit, and gains on sales of unconsolidated companies is helpful in allowing investors to assess the Company’s operations more accurately. 38 The table below provides reconciliations of GAAP to non-GAAP items ( dollars in thousands, except per share data ): Year Ended December 31, 2025 2024 2023 Net income attributable to National HealthCare Corporation $ 120,015 $ 101,927 $ 66,798 Non-GAAP adjustments: Unrealized gains on marketable equity securities (22,344 ) (30,958 ) (14,944 ) Stock-based compensation expense 4,399 4,160 2,782 Gain on sale of property and equipment (3,606 ) – (6,230 ) Operating results for newly-opened operations not at full capacity – 130 2,359 Acquisition-related expenses – 3,266 – Employee retention credit – (9,445 ) – Gain on sale of unconsolidated company – (1,024 ) – Income tax expense on non-GAAP adjustments 5,603 8,806 4,169 Non-GAAP Net Income $ 104,067 $ 76,862 $ 54,934 GAAP diluted earnings per share $ 7.67 $ 6.53 $ 4.34 Non-GAAP adjustments: Unrealized gains on marketable equity securities (1.43 ) (1.98 ) (0.97 ) Stock-based compensation expense 0.28 0.28 0.18 Gain on sale of property and equipment (0.23 ) – (0.42 ) Operating results for newly-opened operations not at full capacity – 0.01 0.15 Acquisition-related expenses – 0.21 – Employee retention credit – (0.61 ) – Gain on sale of unconsolidated company – (0.07 ) – Income tax expense on non-GAAP adjustments 0.36 0.56 0.27 Non-GAAP diluted earnings per share $ 6.65 $ 4.93 $ 3.55 Liquidity, Capital Resources and Financial Condition Sources and Uses of Funds Our primary sources of cash include revenues from the operations of our healthcare operations, management and accounting services, rental income, and investment income.
During the third and fourth quarters of 2024, cash of $13,000,000 was used to pay down the outstanding principal balance of the long-term debt. Dividends paid to common stockholders was $36,964,000, $35,560,000, and $34,604,000 for the years ended December 31, 2024, 2023 and 2022, respectively.
Net cash used in financing activities totaled $42,545,000 for the year ended December 31, 2023. Cash used to pay down the outstanding principal balance of our long-term debt was $97,000,000 and $13,000,000 for the years ended December 31, 2025 and 2024, respectively.
Financing Activities Net cash provided by financing activities totaled $100,344,000 for the year ended December 31, 2024. Net cash used in financing activities totaled $42,545,000 and $47,642,000 for the years ended December 31, 2023 and 2022, respectively. The funding for the White Oak acquisition was provided by the Company’s cash on hand and borrowings of $150,000,000.
We repurchased common shares outstanding in the amount of $14,730,000, $13,502,000, and $2,482,000 for the years ended December 31, 2025, 2024, and 2023, respectively. In 2024, the funding for the White Oak acquisition was provided by the Company’s cash on hand and borrowings under the credit facility of $150,000,000.
Interest expense decreased $239,000 to $324,000 in 2023 from $563,000 in 2022. At December 31, 2023, we have no outstanding long-term debt. Other income Non–operating income increased by $5,519,000, or 49.5% to $16,660,000 compared to the prior year, as further detailed in Note 5 to our consolidated financial statements.
Interest expense increased $2,236,000 to $6,371,000 in 2025 from $4,135,000 in 2024 related to the outstanding long-term debt due to the White Oak acquisition in August 2024. Other income Non–operating income decreased by $1,583,000, or 8.0% to $18,107,000 in 2025 compared to the prior year, as further detailed in Note 4 to our consolidated financial statements.
Investing Activities Net cash used in investing activities totaled $236,693,000 for the year ended December 31, 2024, as compared to $17,568,000 and $5,978,000 for the years ended December 31, 2023 and 2022, respectively. On August, 1, 2024, the acquisition of White Oak resulted in cash used of $215,896,000, as described in Note 2 to our consolidated financial statements.
Investing Activities Net cash used in investing activities totaled $33,858,000 for the year ended December 31, 2025, as compared to $236,693,000 and $17,568,000 for the years ended December 31, 2024 and 2023, respectively. Cash used for property and equipment additions was $36,446,000, $27,600,000, and $27,901,000 for the years ended December 31, 2025, 2024 and 2023, respectively.
The ten new operations listed above attributed to an increase in other operating expenses of $9,082,000 for the year ended December 31, 2023 compared to the prior year.
Other operating expenses as a percentage of net operating revenues and stimulus income was 24.9% and 24.6% for the years ended December 31, 2025 and 2024, respectively. The White Oak operations attributed to an increase of $32,737,000 in other operating expenses for the year ended December 31, 2025 compared to the prior year.
Proceeds from the issuance of common stock totaled $14,268,000, $313,000, and $2,114,000 for 2024, 2023 and 2022, respectively. We repurchased common shares outstanding in the amount of $13,502,000, $2,482,000, and $9,903,000 for the years ended December 31, 2024, 2023, and 2022, respectively.
Dividends paid to common stockholders was $38,704,000, $36,964,000, and $35,560,000 for the years ended December 31, 2025, 2024 and 2023, respectively. Proceeds from the issuance of common stock totaled $14,214,000, $14,268,000, and $313,000 for 2025, 2024 and 2023, respectively.
For the year ended December 31, 2023 our agency nurse staffing expenses decreased $30,682,000, or approximately 44.5%, compared to the prior year.
For the year ended December 31, 2025 our agency nurse staffing expenses decreased $9,335,000, or approximately 66.6%, compared to the same period a year ago. Other operating expenses increased $55,812,000, or 17.4%, to $377,202,000 for the year ended December 31, 2025 compared to $321,390,000 for the prior year.
Cash used for property and equipment additions was $27,600,000, $27,901,000, and $30,200,000 for the years ended December 31, 2024, 2023 and 2022, respectively. For the year ended December 31, 2024, we contributed capital of $14,298,000 to a joint venture, multi-family development that is under construction in Franklin, Tennessee.
For the year ended December 31, 2025, we contributed capital of $5,629,000 for two joint venture, multi-family developments that are under construction in Nashville, Tennessee compared to $14,298,000 for the same period in the prior year.
Net operating revenues and grant income Net patient revenues totaled $1,087,614,000 in 2023, an increase of $58,529,000, or 5.7%, compared to the prior year. The overall average census in owned and leased skilled nursing facilities for 2023 was 87.9% compared to 83.8% in 2022. The composite skilled nursing facility per diem increased 6.7% in 2023 compared to 2022.
The overall average census in owned and leased skilled nursing facilities for 2025 was 89.7% compared to 88.6% in 2024. The composite skilled nursing facility per diem increased 4.0% in 2025 compared to 2024. Medicare and managed care per diem rates increased 5.1% and 3.9%, respectively, in 2025 compared to 2024.
In January 2024, the Company sold its 50% joint venture ownership interest in a homecare agency resulting in proceeds from the sale of $2,100,000. Proceeds from the sale of marketable securities, net of purchases, resulted in cash proceeds of $16,913,000, $17,895,000, and $16,168,000 in 2024, 2023, and 2022, respectively.
In January 2024, the Company sold its ownership interest in a homecare agency resulting in proceeds from the sale of $2,100,000. Financing Activities Net cash used in financing activities totaled $135,955,000 for the year ended December 31, 2025. Net cash provided by financing activities totaled $100,344,000 for the year ended December 31, 2024.
Other operating expenses decreased $1,189,000, or 0.4%, to $288,183,000 for the year ended December 31, 2023 compared to $289,372,000 for the prior year. Other operating expenses as a percentage of net operating revenues and grant income was 25.2% and 26.7% for the years ended December 31, 2023 and 2022, respectively.
Salaries, wages, and benefits as a percentage of net operating revenues and stimulus income was 60.7% compared to 62.0% for the years ended December 31, 2025 and 2024, respectively. The White Oak operations attributed to an increase of $87,199,000 in salaries, wages, and benefits for the year ended December 31, 2025 compared to the prior year.